Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two immunotherapies than patients who received just one immunotherapy drug.
Gerresheimer partners with RxCap to offer connected adherence solutions – Biotech Investments
EQS-News: Gerresheimer AG / Key word(s): Contract/Investment Gerresheimer partners with RxCap to offer connected adherence solutions 29.04.2024 / 13:00 CET/CEST The issuer is solely responsible